SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 163 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.68 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,586,503 | -34.4% | 729,098 | -5.4% | 0.00% | -50.0% |
| Q2 2023 | $16,131,190 | +39.1% | 770,721 | +40.4% | 0.00% | +100.0% |
| Q1 2023 | $11,597,000 | +84580.5% | 549,085 | +2.0% | 0.00% | -50.0% |
| Q4 2022 | $13,695 | -99.9% | 538,126 | -12.7% | 0.00% | 0.0% |
| Q3 2022 | $14,808,000 | +29.5% | 616,251 | +3.7% | 0.00% | 0.0% |
| Q2 2022 | $11,434,000 | +174.3% | 594,302 | +147.8% | 0.00% | +100.0% |
| Q1 2022 | $4,168,000 | +11.7% | 239,829 | +40.7% | 0.00% | – |
| Q4 2021 | $3,731,000 | +160.2% | 170,473 | +127.4% | 0.00% | – |
| Q3 2021 | $1,434,000 | +328.1% | 74,982 | +283.6% | 0.00% | – |
| Q2 2021 | $335,000 | +27.9% | 19,549 | +66.8% | 0.00% | – |
| Q1 2021 | $262,000 | -63.7% | 11,718 | -63.9% | 0.00% | – |
| Q4 2020 | $722,000 | +412.1% | 32,481 | +223.5% | 0.00% | – |
| Q3 2020 | $141,000 | +4.4% | 10,042 | +10.2% | 0.00% | – |
| Q2 2020 | $135,000 | -79.9% | 9,116 | -85.1% | 0.00% | – |
| Q1 2020 | $672,000 | +63.1% | 61,259 | +30.5% | 0.00% | – |
| Q4 2019 | $412,000 | +52.0% | 46,935 | +29.1% | 0.00% | – |
| Q3 2019 | $271,000 | +442.0% | 36,355 | +558.4% | 0.00% | – |
| Q2 2019 | $50,000 | +163.2% | 5,522 | +52.5% | 0.00% | – |
| Q1 2019 | $19,000 | +18.8% | 3,620 | +1.1% | 0.00% | – |
| Q4 2018 | $16,000 | -81.4% | 3,580 | -66.3% | 0.00% | – |
| Q3 2018 | $86,000 | -95.6% | 10,619 | -96.2% | 0.00% | – |
| Q2 2018 | $1,946,000 | -68.0% | 277,162 | -35.1% | 0.00% | -100.0% |
| Q1 2018 | $6,075,000 | +71.1% | 426,941 | +5.3% | 0.00% | 0.0% |
| Q4 2017 | $3,551,000 | -28.5% | 405,360 | -3.4% | 0.00% | 0.0% |
| Q3 2017 | $4,969,000 | -19.0% | 419,670 | -4.4% | 0.00% | 0.0% |
| Q2 2017 | $6,134,000 | +11473.6% | 439,070 | +11266.0% | 0.00% | – |
| Q1 2017 | $53,000 | -27.4% | 3,863 | -62.1% | 0.00% | – |
| Q4 2016 | $73,000 | +1360.0% | 10,185 | +1916.8% | 0.00% | – |
| Q2 2016 | $5,000 | – | 505 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |